VERTEX PHARMACEUTICALS INC (VRTX) Stock News
NASDAQ:VRTX - Nasdaq - US92532F1003 - Common Stock - Currency: USD
VRTX Latest News, Press Relases and Analysis
Top S&P500 movers in Wednesday's session
Get insights into the S&P500 index performance on Wednesday. Explore the top gainers and losers within the S&P500 index in today's session.
What's going on in today's session: S&P500 movers
Stay informed about the performance of the S&P500 index in the middle of the day on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.
Is Merck & Co., Inc. (MRK) the Best Dow Stock?
We recently published a list of The Best and Worst Dow Stocks. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other Dow stocks. The Dow Jones Industrial Average is a benchmark index of the top 30 companies in the US. It represents the strength […]
Amgen Inc. (AMGN): A Bull Case Theory
We came across a bullish thesis on Amgen Inc. (AMGN) on Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on AMGN. Amgen Inc. (AMGN)’s share was trading at $281.22 as of May 2nd. AMGN’s trailing and forward P/E were 25.64 and 13.48 respectively according to Yahoo Finance. Amgen (AMGN) delivered a strong […]
Price Target on CrowdStrike (CRWD) Raised by Japanese Bank After Layoffs
Japanese bank Mizuho Securities increased its price target on IT security giant CrowdStrike (CRWD) to $425 from $410 today. Mizuho remains upbeat on the company’s leadership team after it announced that it would lay off about 5% of its workforce. CRWD also reported that its first-quarter financial results would meet or exceed its previous guidance. […]
Super Micro Computer, Inc. (SMCI): Among Most Popular Stocks on Robinhood in 2025
We recently published a list of 12 Most Popular Stocks on Robinhood in 2025. In this article, we are going to take a look at where Super Micro Computer, Inc. (NASDAQ:SMCI) stands against other most popular stocks on Robinhood in 2025. Individual investors, often called retail investors, on platforms as Robinhood represent an increasingly influential […]
Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip
Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip
Vertex missed Wall Street's Q1 estimates and announced a pause with an early-stage study of its mRNA cystic fibrosis drug. This biotech stock should still generate exceptional returns over the next few years. Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week.
Market Monitor May 7 ( Hims & Hers Health, Upwork UP - Palantir, Monderna DOWN)
Wall Street Retreats as Pharma Stocks Tumble and Trade Uncertainty Lingers
1 S&P 500 Stock with Impressive Fundamentals and 2 to Ignore
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Debt management plans: What you need to know
If you are overwhelmed with debt, a debt management program could provide relief.
Cybersecurity & AI Trends: ICR Managing Directors Dan Brennan & Ryan Flanagan, Live at RSAC 2025
Tech Edge hosted a fireside chat on April 29 at RSAC 2025 in San Francisco with Dan Brennan and Ryan Flanagan, Managing Directors at ICR. The in-person interview was joined by Editor-in-Chief John Jannarone and they discussed how ICR advises its customers in cybersecurity, AI, and investor relations concerns, how the company differentiates itself in […]
S&P 500 Gains & Losses Today: Stocks Fall for Second Day as Palantir, Pharmaceuticals Drop
The S&P 500 slipped 0.8% on Tuesday, May 6, 2025, falling for a second straight day as investors awaited news on U.S. tariff policies and prepared for tomorrow’s Federal Reserve announcement.
Mentions: PLTR
Why Did Vertex Pharmaceuticals Stock Fall On Tuesday?
Vertex posted Q1 EPS and sales below estimates but raised its 2025 revenue outlook, driven by CF drug demand and new product launches in the U.S.
Why Did Vertex Pharmaceuticals Stock Fall On Tuesday?
On Monday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported lower-than-expected first-quarter 2025 earnings. Vertex reported first-quarter adjusted earnings per share of $4.06, down from $4.76 a year ago, missing the consensus of $4.32. The cystic fibrosis-focused company reported sales of $2.77 billion, missing the consensus of $2.85 billion. Total revenue increased by 3%, primarily driven by the continued performance of Trikafta/Kaftrio and an early contribution from the U.S. launch
What's going on in today's session: S&P500 movers
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday.
Stocks Fall On Trade Concerns, Oil And Gold Rally: What's Driving Markets Tuesday?
Wall Street edged lower by midday Tuesday as uncertainty surrounding trade policies lingered, with investors adopting a cautious approach ahead of Wednesday’s Federal Reserve meeting.
Uncover the latest developments among S&P500 stocks in today's session.
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session.
VRTX's Q1 Earnings Lag Estimates, 2025 Revenue View Tightened
Vertex reports weaker-than-expected first-quarter 2025 results. The company tightens its total revenue guidance for 2025.
Top Stock Movers Now: Vertex, DoorDash, Constellation Energy, and More
U.S. equities dropped at midday as the markets awaited any news on tariffs and tomorrow's Federal Reserve decision.
Mentions: F
Vertex Pharmaceuticals Stock Sinks as Costs Soar
Vertex Pharmaceuticals missed first-quarter profit and revenue forecasts as costs jumped.
Why Vertex Pharmaceuticals Stock Is Sinking Today
Which S&P500 stocks are gapping on Tuesday?
Curious about the market action on Tuesday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
Vertex Pharmaceuticals Topples 12% On A Series Of First-Quarter Setbacks
The company paused a study of a cystic fibrosis treatment, right on the heels of a scrapped type 1 diabetes program.
DoorDash Stock Drops as Q1 Revenue Undershoots Analysts' Estimates
DoorDash shares are sinking Tuesday after the food-delivery company posted first-quarter revenue that undershot analysts' forecasts.
Rising Costs Weigh on Vertex Q1 Earnings
Vertex reported Q1 revenue and earnings that fell well short of what most investors were anticipating. Despite the headwinds, Vertex increased the lower end of its full-year revenue guidance, pointing to the ongoing launch of its Alyftrek cystic fibrosis treatment. Vertex's first-quarter financial results didn't keep up with what investors have gotten used to seeing in recent quarters.
Wondering what's happening in today's S&P500 pre-market session?
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the S&P500 top gainers and losers shaping the early market sentiment.
Vertex Pharma Stock’s Retail Buzz Intensifies As 2025 Revenue View Lift Fails To Offset Q1 Miss
The company’s Q1 revenue missed expectations, but the company raised its 2025 revenue guidance, reflecting optimism about growth drivers like cystic fibrosis treatments and its expanding pipeline.
Vertex Says 20,000 Prescriptions Filled for Non-Opioid Pain Drug
Vertex Pharmaceuticals Inc. said more than 20,000 prescriptions have been dispensed for its new non-addictive painkiller, a sign that the drug is gaining some early traction as it attempts to displace opioids.
Vertex Pharmaceuticals (VRTX) Misses Q1 Earnings and Revenue Estimates
Vertex (VRTX) delivered earnings and revenue surprises of -3.79% and 1.72%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: AGEN
Monday's after hours session: top gainers and losers in the S&P500 index
The regular session of the US market on Monday is now over, but let's get a preview of the after-hours session and explore the top S&P500 gainers and losers driving the post-market movements.